IP Library Granted Patent US 10,420,846
Granted Patent B2
US 10,420,846 · App. 16/378,505 · Granted Sep 24, 2019

Bifunctional polypeptides

Inventors: Bent Karsten Jakobsen (Abingdon, GB); Annelise Brigitte Vuidepot (Abingdon, GB); Yi Li (Guangzhou, CN)
Assignee: Immunocore Limited
A61K47/6849A61K47/6425C07K14/7051C07K16/2809C07K16/46A61K38/00C07K2317/622C07K2317/73C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,420,846
App. No.
16/378,505
Granted
Sep 24, 2019
Kind
B2
Abstract

A bifunctional polypeptide comprising a specific binding partner for a peptide-MHC epitope, such as an antibody or T cell receptor, and an immune effector, such as an antibody or a cytokine, the immune effector part being linked to the N-terminus of the peptide-MHC binding part.

Claims (11)

1. A bifunctional molecule, comprising:

(i) a polypeptide binding partner, wherein the polypeptide binding partner binds specifically to a given pMHC epitope, and

(ii) an immune effector polypeptide,

wherein:

the N-terminus of the pMHC binding partner is linked to the C-terminus of the immune effector polypeptide,

the pMHC binding partner is a single chain antibody (scFv), and

the immune effector polypeptide is a single chain anti-CD3 antibody.

2. The bifunctional molecule of claim 1 , wherein the immune effector anti-CD3 scFv comprises the CDRs of SEQ ID NO: 3.

3. The bifunctional molecule of claim 2 , wherein the immune effector anti-CD3 scFv comprises SEQ ID NO: 3.

4. The bifunctional molecule of claim 1 , wherein the immune effector antibody comprises the CDRs of BMA031.

5. The bifunctional molecule of claim 1 , wherein the immune effector antibody comprises the CDRs of 12F6.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2025
From: ADAPTIMMUNE LIMITED
To: IMMUNOCORE LIMITED
Reel/Frame 072896/0339 →
RELEASE OF SECURITY INTEREST Recorded Nov 11, 2024
From: BIOPHARMA CREDIT PLC
To: IMMUNOCORE LIMITED
Reel/Frame 069197/0672 →
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2022
From: OXFORD FINANCE LUXEMBOURG S.À R.L
To: IMMUNOCORE LIMITED; IMMUNOCORE LLC; IMMUNOCORE COMMERCIAL LLC
Reel/Frame 061916/0493 →
PATENT SECURITY AGREEMENT Recorded Nov 8, 2022
From: IMMUNOCORE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 061899/0866 →
SECURITY INTEREST Recorded Nov 6, 2020
From: IMMUNOCORE LIMITED; IMMUNOCORE LLC; IMMUNOCORE COMMERCIAL LLC
To: OXFORD FINANCE LUXEMBOURG S.À R.L., REGISTERED WITH THE LUXEMBOURG COMMERCIAL REGISTER UNDER NUMBER B243395, ACTING IN RESPECT OF ITS COMPARTMENT 1
Reel/Frame 054344/0218 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2019
From: LI, YI; JAKOBSEN, BENT KARSTEN; VUIDEPOT, ANNELISE BRIGITTE
To: IMMUNOCORE LIMITED
Reel/Frame 049756/0895 →